AIMS: There is increasing evidence that erlotinib exposure correlates well with treatment outcome. In this report we present a case of therapeutic drug monitoring of erlotinib in a patient with a gastric ulcer, treated with the proton pump inhibitor pantoprazole. This agent may cause an unwanted, but not always unavoidable, interaction since absorption of erlotinib is pH dependent. METHODS: Erlotinib trough concentrations were monitored in a patient during treatment with orally and intravenously administered pantoprazole. RESULTS: Erlotinib trough concentrations were diminished during high dose intravenously administered pantoprazole, but returned to normal when the dose was reduced and pantoprazole was administered orally. CONCLUSIONS: More studies are needed to assess the dose dependency of the interaction between pantoprazole and erlotinib. Furthermore, we advise to monitor closely erlotinib plasma concentrations and adjust the erlotinib dose accordingly when a clinically relevant interaction is suspected and no proper dosing guidelines are available.
AIMS: There is increasing evidence that erlotinib exposure correlates well with treatment outcome. In this report we present a case of therapeutic drug monitoring of erlotinib in a patient with a gastric ulcer, treated with the proton pump inhibitor pantoprazole. This agent may cause an unwanted, but not always unavoidable, interaction since absorption of erlotinib is pH dependent. METHODS:Erlotinib trough concentrations were monitored in a patient during treatment with orally and intravenously administered pantoprazole. RESULTS:Erlotinib trough concentrations were diminished during high dose intravenously administered pantoprazole, but returned to normal when the dose was reduced and pantoprazole was administered orally. CONCLUSIONS: More studies are needed to assess the dose dependency of the interaction between pantoprazole and erlotinib. Furthermore, we advise to monitor closely erlotinib plasma concentrations and adjust the erlotinib dose accordingly when a clinically relevant interaction is suspected and no proper dosing guidelines are available.
Authors: M Hidalgo; L L Siu; J Nemunaitis; J Rizzo; L A Hammond; C Takimoto; S G Eckhardt; A Tolcher; C D Britten; L Denis; K Ferrante; D D Von Hoff; S Silberman; E K Rowinsky Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 44.544
Authors: A G Lankheet; M J X Hillebrand; M H G Langenberg; H Rosing; A D R Huitema; E E Voest; J H M Schellens; J H Beijnen Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2009-09-06 Impact factor: 3.205
Authors: Ashok Rakhit; Michael P Pantze; Scott Fettner; Hannah M Jones; Jean-Eric Charoin; Myriam Riek; Bert L Lum; Marta Hamilton Journal: Eur J Clin Pharmacol Date: 2007-11-14 Impact factor: 2.953
Authors: Charles M Rudin; Wanqing Liu; Apurva Desai; Theodore Karrison; Xuemin Jiang; Linda Janisch; Soma Das; Jacqueline Ramirez; Balasubramanian Poonkuzhali; Erin Schuetz; Donna Lee Fackenthal; Peixian Chen; Deborah K Armstrong; Julie R Brahmer; Gini F Fleming; Everett E Vokes; Michael A Carducci; Mark J Ratain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Serena Marchetti; Nienke A de Vries; Tessa Buckle; Maria J Bolijn; Maria A J van Eijndhoven; Jos H Beijnen; Roberto Mazzanti; Olaf van Tellingen; Jan H M Schellens Journal: Mol Cancer Ther Date: 2008-08 Impact factor: 6.261
Authors: David M Peereboom; Manmeet S Ahluwalia; Xiaobu Ye; Jeffrey G Supko; Sarah L Hilderbrand; Surasak Phuphanich; L Burt Nabors; Myrna R Rosenfeld; Tom Mikkelsen; Stuart A Grossman Journal: Neuro Oncol Date: 2013-01-17 Impact factor: 12.300
Authors: Roelof W F van Leeuwen; Frank G A Jansman; Nicole G Hunfeld; Robert Peric; Anna K L Reyners; Alex L T Imholz; Jacobus R B J Brouwers; Joachim G Aerts; Teun van Gelder; Ron H J Mathijssen Journal: Clin Pharmacokinet Date: 2017-07 Impact factor: 6.447
Authors: Nesaretnam Barr Kumarakulasinghe; Nicholas Syn; Yu Yang Soon; Atasha Asmat; Huili Zheng; En Yun Loy; Brendan Pang; Ross Andrew Soo Journal: Oncotarget Date: 2016-12-20
Authors: Andrea Gruber; Martin Czejka; Philipp Buchner; Marie Kitzmueller; Nairi Kirchbaumer Baroian; Christian Dittrich; Azra Sahmanovic Hrgovcic Journal: Cancer Chemother Pharmacol Date: 2018-02-16 Impact factor: 3.333